155 related articles for article (PubMed ID: 25027498)
1. New pancreatic adenocarcinoma in a Crohn's patient treated with tumor necrosis factor (TNF) inhibitors for 6 months.
Patel R; Lara S; Johnson J; Kulkarni P
J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():226-9. PubMed ID: 25027498
[No Abstract] [Full Text] [Related]
2. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
Cravo M; Silva R; Serrano M
BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232
[TBL] [Abstract][Full Text] [Related]
4. [Adalimumab in Crohn's disease - data from real life].
López San Román A; Van Domselaar M; Garrido E
Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
[No Abstract] [Full Text] [Related]
5. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
6. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
Haennig A; Bonnet D; Thebault S; Alric L
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
[No Abstract] [Full Text] [Related]
7. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
8. PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
Parkes GC; Hedin CRH
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):489-491. PubMed ID: 38640938
[No Abstract] [Full Text] [Related]
9. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
10. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
[TBL] [Abstract][Full Text] [Related]
11. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
Heidemann J; Kucharzik T
Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
[No Abstract] [Full Text] [Related]
12. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
14. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.
Broge T; Nguyen N; Sacks A; Davis M
Inflamm Bowel Dis; 2013 Apr; 19(5):E75-7. PubMed ID: 23435403
[No Abstract] [Full Text] [Related]
15. Adenocarcinoma of the rectum and anus in a patient with Crohn's disease treated with infliximab.
Egea-Valenzuela J; Belchí-Segura E; Essouri N; Sánchez-Torres A; Carballo-Alvarez F
Rev Esp Enferm Dig; 2010 Jul; 102(8):501-4. PubMed ID: 20670073
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
18. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
Kabaçam G; Törüner M
Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
[TBL] [Abstract][Full Text] [Related]
20. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
